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ABSTRACT
 
Celiac disease is a gluten-induced autoimmune enteropathy characterized by the presence of tissue tran- glutaminase (tTG) autoantibodies. A disposable 
electrochemical immunosensor (EI) for the detection of IgA and IgG type anti-tTG autoantibodies in real patient’s samples is presented. Screen-printed car- bon 
electrodes (SPCE) nanostructurized with carbon nanotubes and gold nanoparticles were used as the transducer surface. This transducer exhibits the excellent 
characteristics of carbon–metal nanoparticle hybrid conjugation and led to the amplification of the immunological interaction. The immunosensing strategy consisted of 
the immobilization of tTG on the nanostructured electrode surface followed by the electrochemical detection of the autoantibodies present in the samples using an 
alkaline phosphatase (AP) labelled anti-human IgA or IgG antibody. The analytical signal was based on the anodic redissolution of enzymatically generated silver by cyclic 
voltammetry. The results obtained were corroborated with a commercial ELISA kit indicating that the electrochemical immunosensor is a trustful analytical screening 
tool. 
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1. Introduction 
 
Celiac disease (CD) is a gluten-sensitive enteropathy triggered by 
dietary gluten in genetically susceptible individuals. CD has a strong 
association with human leucocyte antigen HLA-DQ2 and HLA-DQ8. 
Although the presence of these HLA proteins is necessary for developing 
celiac disease, it is not enough since about 30% of the healthy population 
possess them (McGough and Cummings, 2005). CD patients normally 
experience a massive immune reaction that leads to the production of 
autoantibodies and to the destruction of the small-intestinal mucosal 
morphology and intestinal dysfunc- tion (Lindfors et al., 2009). Over 
time there has been a substantial increase in background prevalence of 
the disease, affecting around 1% of most populations (Lohi et al., 2007; 
Rubio-Tapia and Murray, 2010). 
The diagnostic criteria for CD, which require endoscopy with small 
bowel biopsy, have been changing over the last few decades, especially 
due to the advent of serological tests with higher sen- sitivity and 
specificity for the measurement of these antibodies (Neves et al., 
2010). Serologic testing has impacted the rate of 
 
 
 
diagnosis as well as the understanding of the epidemiology of this 
autoimmune condition (Rubio-Tapia and Murray, 2010). Current 
diagnostic routines include serology in combination with the his- 
tological examination of at least one biopsy that demonstrates 
mucosal villous atrophy while the patient consumes gluten con- taining 
food. When a decline of CD-related autoantibodies and the remission 
of the symptoms are observed when the patient is on a gluten-free 
diet, the second biopsy may not be needed (Hill et al., 2005). 
Therefore, serological tests, without surrogating the histological exam, 
have been used as a front-line strategy for screening candidates for the 
need of a duodenal biopsy (Sugai et al., 2010), avoiding such unnecessary 
invasive exams. Moreover many patients have little or no gastrointestinal 
symptoms while present- ing extraintestinal syntomatology (Briani et al., 
2008; Lindfors et al., 2009). Another important aspect to consider in a 
serological diag- nosis is the selective IgA deficiency of the patient. If 
an individual presents a negative serological test but exhibits 
suggestive symp- toms, the possibility of IgA deficiency should be 
considered and an IgG test must be performed. The identification of 
tissue transg- lutaminase (tTG) as the antigen against which the 
autoantibodies are directed, has led to a greater understanding of the 
pathogen- esis of CD and to the development of improved serological 
tests (Alaedini and Green, 2005; Hill and McMillan, 2006; Armstrong 
et al., 2011). The common methodology for CD clinical serologi- cal 
diagnostic purposes is an enzyme-linked immunosorbent assay (ELISA). 
ELISA tests that measure the antibodies directed against 
 
  
tTG have high diagnostic sensitivity and specificity for the detection of 
CD. In an ELISA, antibodies are detected after several incubation, 
washing and separation steps. An alternative to these high-cost and 
laborious assays could be electrochemical immunosensors (EIs). EIs 
combine the specificity inherent to antigen–antibody inter- actions 
with the high sensitivity of electrochemical transduction (Alonso-
Lomillo et al., 2010), offering new exciting alternatives to the 
conventional immunochemical tests which are based on indi- rect 
detection, compromising real-time analysis. 
There are few publications concerning the development of EIs to aid 
the diagnosis of CD. As far as we are concerned, regarding the use of EIs for 
the detection of autoantibodies directed against tTG, only 3 studies are 
published. An impedimetric immunosensor for the detection of 
antibodies against transglutaminase in human serum was presented by 
Balkenhohl and Lisdat (2007). The immunosensor was based on the 
immobilization of transglutaminase onto dispos- able screen-printed 
gold electrodes which were modified with a polyelectrolyte layer of 
poly(sodium 4-styrenesulfonic acid). Using impedance spectroscopy a 
qualitative analysis was carried out. According to the authors, an 
acceptable sensitivity was achieved but the results suggest a lower 
precision than ELISA. In a sec- ond study (Pividori et al., 2009) an 
amperometric electrochemical immunosensor based on the physical 
adsorption of tTG from guinea pig liver onto graphite–epoxy composite 
(GEC) electrodes was pro- posed. For 10 positive and 10 negative 
processed serum samples a sensitivity of 70% and a specificity of 100% 
were achieved when compared with the commercial ELISA method. 
Only a qualitative study was performed and no correlation between 
the analyti- cal signal and the amount of antibodies present in the 
samples was established. More recently, an electrochemical 
immunosen- sor for the detection of human anti-tissue 
transglutaminase IgA and IgG antibodies in real samples by the 
covalent attachment of tTG to gold electrodes by the use of self-
assembled monolayers of a group carboxylic-terminated bipodal 
alkanethiol was developed (Dulay et al., 2011). The results obtained 
with the immunosensor showed a good correlation with those obtained 
using a commercial ELISA. 
Baring in mind that one of the big challenges of analytical 
chemistry is the development of accurate and sensitive meth- ods 
that allow rapid in situ analyses, a disposable electrochemical 
immunosensor for CD clinical evaluation through the detection of 
antibodies to tTG in human serum is proposed. The electro- 
chemical transducer surface consists of a screen-printed carbon 
electrode (SPCE) modified with multiwalled carbon nanotubes 
(MWCNTs) and gold nanoparticles (NPAus). Carbon nanostruc- 
ture/metal nanoparticle hybrids have been widely exploited in the last 
years for electrochemical sensing applications since the conjugation of 
each material enhances their individual properties (Agüí et al., 2008). 
Therefore the immunosensing strategy con- sisted on the 
immobilization, by physical adsorption, of human tTG on a screen-
printed carbon electrode modified with carbon nanotubes and gold 
nanoparticles. The nanomaterials are used as an efficient amplification 
interface between the biorecogni- tion process and the electrochemical 
transduction event. After the reaction with the patient’s serum a 
secondary enzyme-labelled antibody is used to obtain electrochemical 
detection using 3- indoxyl phosphate and silver ions. The results 
indicate that the proposed immunosensor can be competitive with the 
standard methodology. 
 
2. Materials and methods 
 
2.1. Instrumentation 
 
Voltammetric experiments were performed with an Autolab PGSTAT 
12 (Eco Chemie, The Netherlands) potentiostat/galvanostat 
interfaced to an AMD K-6 266 MHz computer system and con- trolled 
by Autolab GPES 4.8 (software version for Windows 98). All the 
measurements were carried out at room temperature. Dis- posable 
screen-printed carbon electrodes (SPCEs) were purchased from 
DropSens (Spain). These electrodes incorporate a conven- tional three-
electrode configuration, printed on ceramic substrates (3.4 × 1.0 cm). 
Both the working- (disk-shaped 4 mm diameter) and counter electrodes 
are made of carbon inks, whereas the pseudoref- erence electrode and 
the electric contacts are made of silver. A ring-shaped layer printed 
around the working electrode constitutes the reservoir (50 µL) of the 
electrochemical cell. The SPCEs were easily connected to the 
potentiostat through a specific DropSens connector (Spain). 
 
2.2. Chemicals and immunochemicals 
 
Tris(hydroxymethyl)aminomethane (Tris), magnesium nitrate, 
bovine serum albumin fraction V (BSA), were purchased from 
Sigma (Spain). Carboxyl modified multiwalled carbon nanotubes 
(MWCNTs) were purchased from Nanocyl (Belgium). Standard gold 
tetrachloroaurate (AuCl4
−), silver nitrate, hydrochloric acid (37%) and 
nitric acid (HNO3) were obtained from Merck (Germany). Biosynth 
(Switzerland) supplied the 3-indoxyl phosphate disodium salt (3-IP). 
Human tissue transglutaminase (recombinantly pro- duced in insect 
cells) was purchased from Zedira (Germany). Goat anti-human IgG 
(Fc specific) conjugated with alkaline phos- phatase (anti-H-IgG-AP) 
was purchased from Sigma (Spain) and goat anti-human IgA (alpha 
chain specific) labelled with alkaline phosphatase (anti-H-IgA-AP) was 
provided by Invitrogen (Spain). The validation of the developed 
procedure was performed with anonymous sera samples analysed by 
Varelisa Celikey and Varelisa Celikey IgG ELISA kits supplied by Phadia 
(Germany). Each kit con- tained six standard serum samples (0, 3, 7, 16, 
40, 100 U mL−1) and a positive and a negative control. The kit’s 
manufacturers propose a range of values with clinical significance for the 
analysis of the sam- ples: an equivocal result lays between 5 and 8 U mL−1 
in the case of IgA detection and between 7 and 10 U mL−1 for IgG 
determination. Below and above these values the samples are classified 
as nega- tive or positive, respectively, for CD. Ultrapure water obtained 
with a Millipore Direct-QTM purification system from Millipore Ibérica 
S.A. (Spain) was used throughout this work. All chemicals employed were 
of analytical reagent grade. 
Working solutions of tTG were prepared in a 0.1 M Tris–HNO3 pH 
7.2 buffer. Working solutions of the secondary alkaline phos- phatase 
labelled antibodies were prepared in 0.1 M Tris–HNO3 pH 
7.2 containing 2 mM Mg(NO3)2. A solution containing 1.0 mM 3-IP and 
0.4 mM silver nitrate was prepared daily in 0.1 M Tris–HNO3 pH 
9.8 and 20 mM Mg(NO3)2 and stored in opaque tubes at 4 
◦C. The 
MWCNTs solutions were prepared by dilution of the concentrated 
solution with a mixture of DMF:water (1:1). The gold tetrachloroau- rate 
solution was prepared in 0.1 M HCl. 
 
2.3. Electrode nanostructuration 
 
The modification of the screen-printed electrodes with nanohy- brid 
structures was previously studied in our group (Neves et al., 2011). 
Single-use SPCEs were modified with 4 µL of a 0.1 mg mL−1 MWCNTs 
dispersion and the solution was left to dry at room temperature until 
its complete evaporation. Then, the MWCNTs- modified electrode was 
carefully washed with water and dried at room temperature. The coating 
process was followed by in situ elec- trochemical deposition of gold 
nanoparticles (NPAus) by applying a constant current intensity of −5 µA 
for 60 s in an acidic solution of 0.1 mM AuCl4
−. The resulting SPCE–
MWCNT–NPAus were rinsed with water and were ready to use. 
  
 
 
Fig. 1.  Schematic representation of the immunosensor architecture used in this study. 
 
 
2.4. Immunosensor for the detection of anti-tTG antibodies 
 
The following procedure (Fig. 1) describes an optimized assay. The 
SPCE–MWCNT–NPAus working electrodes were coated with 10 µL of 
a 0.1 µg µL−1 tTG solution and left to incubate overnight at 4 ◦C. After 
the incubation step the electrode was washed with 
0.1 M Tris–HNO3 pH 7.2 buffer. Free surface sites of the tTG- 
modified electrodes were blocked with a BSA solution (2% in 0.1 M 
Tris–HNO3 pH 7.2) during 30 min. The detection of anti-tTG anti- 
bodies was accomplished by incubating the immunosensors with 
human serum samples for 60 min followed by a washing step with a 
0.1 M Tris–HNO3 pH 7.2 buffer containing 2 mM Mg(NO3)2. Finally, the 
immunosensor was incubated with an anti-H-IgA-AP (1:30,000) or an 
anti-H-IgG-AP (1:50,000) solution for 60 min and washed with a 0.1 
M Tris pH 9.8 buffer containing 20 mM 2 mM Mg(NO3)2. The 
enzymatic reaction was carried out by dropping a 40-µL aliquot of a 
solution containing 1.0 mM 3-IP and 0.4 mM silver nitrate on the 
immunosensor’s surface. The enzymatically deposition of silver 
catalyzed by alkaline phosphatase (AP) was studied previously and the 
work was already reported (Fanjul- Bolado et al., 2007). For the 
generation of the analytical signal an alkaline phosphatase labelled 
secondary antibody was employed. AP worked as the enzymatic label 
and a mixture of 3-indoxyl phos- phate with silver ions (3-IP/Ag+) as the 
substrate. AP hydrolyzes 3-IP resulting in a indoxyl intermediate that 
will reduce the silver ions presents in solution resulting in metallic silver 
(Ag0) and indigo blue (I). Thus, the silver enzymatically deposited on 
the electrode surface can be detected through the anodic peak of the 
silver when an anodic stripping scan is carried out. After 20 min of 
reaction, a cyclic voltammogram was recorded from −0.002 V to +0.4 V, 
at scan rate of 50 mV s−1, to obtain the electrochemical oxidation 
current of the enzymatically deposited silver. 
 
3. Results and discussion 
 
left overnight at 4 ◦C and avoiding the evaporation to dryness of the 
solution. Non-specific adsorption was effectively blocked with the 
addition of 40 µL BSA (2%) during 30 min. The sensing phase of the 
immunosensor was then completed. The analyti- cal signals obtained 
with a nanohybrid-modified electrode   and a non-nanostructured 
electrode were compared. Fig. 2 shows cyclic voltammograms 
obtained for the detection of anti-tTG IgA antibodies using a tTG-
modified SPCE as well as a tTG-modified SPCE–MWCNT–NPAus. The 
obtained results indicate that the pres- ence of the nanomaterials improves 
the faradaic/capacitive current ratio. The conjugation of MWCNTs and 
NPAus has already demon- strated to possess important analytical 
properties for biosensors due to the metal nanoparticles’ ability to 
adsorb proteins without compromising their bioactivity, and the 
excellent electrocatalyt- ical properties of the carbon nanotubes (Agüí 
et al., 2008; Neves et al., 2011). The differences observed in the peaks 
potential can be explained due to the presence of gold nanoparticles 
on the transducer surface. Gold nanoparticles  facilitate  the reduction 
of silver and, as a consequence of that, the anodic peak of the 
silver is shifted toward less positive potentials (Hernández-Santos et al., 
2000; de la Escosura-Mun˜ iz et al., 2004; Lee et al., 2004).  In 
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3.1. Optimization of the immunosensing strategy 
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The working area of the SPCE–MWCNT–NPAus (see 
Supplementary material) was  coated  with  different  amounts of tTG. 
The highest analytical signals and the best reproducibility were 
obtained using 10 µL of a 0.1 µg µL−1  tTG solution     when 
Fig. 2. Effect of the transducer surface on the  analytical  signal  for  the detec- tion of 
anti-tTG IgA autoantibodies using a tTG-modified SPCE (grey line) and a tTG-
modified SPCE–MWCNT–NPAus (black line). Experimental conditions: tTG 
0.1 µg µL−1 ; BSA 2%; control samples diluted 1:2; anti-H-IgA-AP 1:30,000; 3-IP, 
1.0 mM; Ag+, 0.4 mM. Cyclic voltammetric scans from −0.002 V to +0.4 V at a scan rate 
of 50 mV s−1 . 
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Fig. 3. Cyclic voltammograms obtained in the analysis of positive (black lines) and 
negative (grey lines) serum samples with tTG-modified (solid lines) and non- tTG-
modified nanohybrid electrodes (dashed lines). Experimental conditions: tTG 
0.1 µg µL−1 ; BSA 2%; serum samples diluted 1:200; anti-H-IgA-AP 1:30,000; 3-IP 
1.0 mM; Ag+ 0.4 mM. Cyclic voltammetric scans from −0.002 V to +0.4 V at a scan rate 
of 50 mV s−1 . 
 
 
Fig. 3 voltammograms are shown for the analysis of a positive and a 
negative sample using a tTG-modified SPCE–MWCNT–NPAus and 
non-tTG-modified SPCE–MWCNT–NPAus. The data show that the 
stripping peak current intensity of silver depends on the concentration 
of the alkaline phosphatase labelled antibodies, which in turn depends 
of the amount of autoantibodies in the analysed samples. Therefore 
the measured analytical signals  for 
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a positive and a negative sample analysed with the complete sensing 
platform (electrode with tTG) can be perfectly distin- guished, the 
highest peak corresponding to the determination of autoantibodies in 
the positive sample. When the same samples were analysed with an 
incomplete immunosensing strategy (i.e. electrode without antigen) two 
similar peaks with current inten- sities of approximately 8 µA were 
obtained. Furthermore, these current values are comparable to those 
obtained with a negative sample assayed using a tTG-modified electrode. 
These results indicate that these peaks correspond to the sensor’s 
background signal resulting from residual non-specific protein binding 
that occur despite of the effective surface blocking and are due to the 
presence of several different immunoglobulins and other proteins in the 
serum samples. Moreover, the obtained current difference for a positive  
sample  analysed  in  the  presence  or  absence  of tTG on the electrode 
surface, indicates that the immunological reaction between antigen and 
autoantibodies was successfully performed. 
 
3.2. Reproducibility 
 
A precision study of the immunosensor’s performance was carried out 
by evaluating the reproducibility of two interday immunosensing assays 
of positive as well as negative human anti- tTG antibodies sera. Three 
measurements using three separate sensors were preformed on each day 
and the obtained results indi- cate a good reproducibility of the 
immunosensor, with an average relative standard deviation (RSD) of 
9.32% for the negative samples and 2.01% for the positive samples. 
 
3.3. Evaluation of real patient’s samples 
 
To be able to classify samples as being positive, negative or 
ambiguous, a cut-off value was defined as the average peak cur- rent 
intensity plus three times the standard deviation obtained for 8 negative 
samples. These values are 7.3 µA and 12 µA for anti-tTG IgA and IgG 
antibodies, respectively. The developed immunosensor 
Fig. 4. Peak current intensities obtained in the determination of (a) IgA and (b) IgG 
anti-tTG autoantibodies in real patient’s samples using the optimized electro- chemical 
immunosensor. Experimental conditions: tTG 0.1 µg µL−1 ; BSA 2%; serum samples 
diluted 1:200; anti-H-IgA-AP 1:30,000 (a) and anti-H-IgA-AP 1:50,000 (b); 3-IP 1.0 mM; 
Ag+ 0.4 mM (average data ± standard deviation are indicated (n = 3)). 
 
 
was then applied to the analysis of 10 different human sera from real 
patients for the detection of anti-tTG class A and G antibod- ies. The 
results are presented in Fig. 4 and show that four samples were positive 
for celiac disease (S1–S4), presenting both IgA and IgG anti-tTG 
antibodies, sample 5 was only positive for IgG detection, which 
indicates that the donor is a celiac patient with selective IgA deficiency, 
and the remaining five samples correspond to healthy individuals (S6–
S10). 
 
 
3.4. Calibration plot for the determination of anti-tTG antibodies 
in human serum samples 
 
SPCE–MWCNT–NPAus modified with tTG were used to establish a 
relationship between the stripping peak current intensity and the 
concentration of anti-tTG antibodies, in arbitrary units, using the 
calibrators of the commercial ELISA kits. The peak current intensi- ties 
were extrapolated to the calibrator solutions plot to convert the results in 
arbitrary units to be able to compare the results, in quan- titative terms, 
with the results obtained using the ELISA. The insets (calibration plots) 
shown in Fig. 5 present the relationship between the peak current 
intensity and the concentration of anti-tTG anti- bodies present in the 
assayed calibrators. As can be observed the voltammetric response 
of the sensor is not linear within the entire analysed concentration 
range. Saturation is achieved after 40 U mL−1. Using the optimized 
conditions linear regression equa- 
tions of  ip  (µA) = (0.53 ± 0.02)  [antibody  U mL−1] + (1.66 ± 0.48) (r = 
0.994) and ip (µA) = 0.47 ± 0.01 [antibody U mL−1] + 1.93 ± 0.03 (r = 
0.999)  were  achieved  for  the  determination  of  anti-tTG  IgA 
and IgG autoantibodies, respectively. Examples of cyclic voltam- 
mograms obtained within the linear ranges are also shown in Fig. 5. 
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Data given in Table 1 indicate that the results of quantitative 
analyses obtained with the electrochemical immunoassay do not 
perfectly match the ELISA results. However, the qualitative results (i.e. 
positive or negative) match perfectly. Moreover to the clini- cal 
diagnostic of this autoimmune condition the most significant aspect is 
the qualitative detection of the serological markers. For this reason the 
results achieved with the immunosensor were sup- ported by those 
obtained with the commercial ELISA assay. 
 
 
4. Conclusions 
 
Combining the advantages of the strong antibody–antigen inter- action 
with the sensitivity of the electrochemical techniques, a new 
disposable electrochemical immunosensor for the detection of gluten-
induced celiac disease-specific anti-tissue transglutam- inase IgA and 
IgG autoantibodies in real patients’ samples was developed. Tissue 
transglutaminase was successfully immobilized on a nanohybrid (carbon 
nanotube/gold nanoparticle) screen- printed carbon electrode surface 
and 10 different human sera were assayed. The results obtained were 
corroborated with a commer- cial ELISA kit indicating that the 
electrochemical immunosensor is a trustful analytical screening tool. 
The proposed miniatur- ized electrochemical immunoassay can be a 
good alternative to the conventional optical screening assays. 
Moreover the employ- ment of disposable SPCEs as electrochemical 
transducer surfaces, in detriment of classical solid electrodes, avoids 
some problems as memory effects and tedious cleaning processes. 
SPCE-based biosensors allows to perform a point-of-care diagnostic 
and as a consequence the decentralization of clinical applications. A 
biosen- sor developed on a screen-printed electrode can be a portable 
and ready-to-use device, able to be competitive not only with tradi- 
tional methods, but also with other biosensors. 
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Table 1 
Comparison of the analyses of anti-tTG antibody concentration in different human sera using the developed electrochemical immunosensor and a commercial ELISA. 
 
Real patient’s sera Electrochemical immunosensor   ELISA   
 Anti-tTG IgA antibodiesa Anti-tTG IgG antibodiesa  Anti-tTG IgA antibodiesb Anti-tTG IgG antibodiesb 
S1 52.05 ± 6.22 36.28 ± 0.71  82.96 ± 0.29 35.21 ± 1.00  
S2 53.24 ± 2.32 64.06 ± 2.24  81.95 ± 0.18 87.59 ± 1.14  
S3 58.39 ± 2.91 30.68 ± 0.50  59.91 ± 0.01 53.95 ± 0.36  
S4 31.94 ± 2.99 36.85 ± 2.82  61.75 ± 0.11 91.97 ± 0.65  
S5 2.59 ± 1.32 40.21 ± 2.27  0.030 ± 0.001 35.48 ± 0.39  
S6 3.92 ± 0.72 5.74 ± 2.36  0.086 ± 0.003 0.314 ± 0.001  
S7 0.44 ± 0.91 4.22 ± 3.26  0.088 ± 0.007 0.409 ± 0.014  
S8 1.65 ± 0.58 2.99 ± 2.87  0.030 ± 0.003 0.242 ± 0.007  
S9 1.10 ± 0.84 5.93 ± 1.44  0.035 ± 0.012 0.426 ± 0.001  
S10 3.91 ± 0.24 3.28 ± 0.66  0.100 ± 0.002 0.532 ± 0.050  
a Concentrations are given in U mL−1 (average data ± standard deviation are indicated (n = 3)). 
b Concentrations are given in U mL−1 (average data ± standard deviation are indicated (n = 2)). 
i 
/ 

A
 
i 
/ 

A
 
  
References 
 
Agüí, L., Yán˜  ez-Seden  ˜o, P.Y., Pingarrón, J.M., 2008. Anal. Chim. Acta 622, 11–47. Alaedini, 
A., Green, P.H., 2005. Ann. Intern. Med. 142,    289–298. 
Alonso-Lomillo, M.A., Domínguez-Renedo, O., Arcos-Martínez, M.J., 2010. Talanta 82,   
1629–1636. 
Armstrong, D., Don-Wauchope, A.C., Verdu, E.F., 2011. Can. J. Gastroenterol. 25, 193–
197. 
Balkenhohl, T., Lisdat, F., 2007. Anal. Chim. Acta 597, 50–57. 
Briani, C., Samaroo, D., Alaedini, A., 2008. Autoimmun. Rev. 7,    644–650. 
de la Escosura-Mun  ˜iz, A., González-García, M.B., Costa-García, A., 2004. Electroanal- ysis  
16,  1561–1568. 
Dulay, S., Lozano-Sánchez, P., Iwuoha, E., Katakis, I., O’Sullivan, C., 2011. Biosens. 
Bioelectron. 26, 3852–3856. 
Fanjul-Bolado, P., Hernández-Santos, D., González-García, M.B., Costa-García, A., 2007.  
Anal.  Chem.  79,  5272–5277. 
Hernández-Santos, D., González-García, M.B., Costa-García, A., 2000. Electroanalysis 12,   
1461–1466. 
 
Hill, I.D., Dirks, M.H., Liptak, G.S., Colletti, R.B., Fasano, A., Guandalini, S., Hoffen- berg, 
E.J., Horvath, K., Murray, J.A., Pivor, M., Seidman, E.G., 2005. J. Pediatr. 
Gastroenterol.  Nutr.  40, 1–19. 
Hill, P.G., McMillan, S.A., 2006. Ann. Clin. Biochem. 43, 105–117. Lee, 
T.M., Cai, H., Hsing, I.M., 2004. Electroanalysis 16, 1628–1631. Lindfors, 
K., Kaukinen, K., Mäki, M., 2009. Amino Acids 36, 685–691. 
Lohi, S., Mustalahti, K., Kaukinen, K., 2007. Aliment. Pharmacol. Ther. 26, 1217–1225. 
McGough, N., Cummings, J.H., 2005. Proc. Nutr. Soc. 64, 434–450. 
Neves, M.M.P.D., González-García, M.B., Nouws, H.P.A., Delerue-Matos, C., Santos- Silva, 
A., Costa-García, A., 2010. Anal. Bioanal. Chem. 397, 1743–1753. 
Neves, M.M.P.D., González-García, M.B., Delerue-Matos, C., Costa-García, A., 2011. 
Electroanalysis 23, 63–71. 
Pividori, M.I., Lermo, A., Bonanni, A., Alegret, S., del Valle, M., 2009. Anal.   Biochem. 
388, 229–234. 
Rubio-Tapia, A., Murray, J.A., 2010. Curr. Opin. Gastroenterol. 26, 116–122. 
Sugai, E., Moreno, M.L., Hwang, H.J., Cabanne, A., Crivelli, A., Nachman, F., Vázquez, H., 
Niveloni, S., Argonz, J., Mazure, R., La Motta, G., Caniggia, M.E., Smecuol, E., Chopita, 
N., Gómez, J.C., Maurin˜  o, E., Bai, J.C., 2010. World J. Gastroenterol. 16, 3144–3152. 
